OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
02 aug 2007 - 22:20
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces 2007 first half-year results
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO), the drug delivery and development company, announces today its results for the six-month period ended 30 June 2007.
Financial and product highlights
- Promising initial results for Locteron™ Phase IIa clinical study
- Acquisition of full rights to PolyActive™ technology from IsoTis
- Contract Development revenues increased by 10% and consolidated gross revenues by 17%
- Appointment of new Scientific Advisory Board members
- Re-evaluation of product pipeline and discontinuation of growth hormone product
Gerelateerde downloads
Datum laatste update: 20 december 2025